Characteristics of recurrent genital herpes simplex infections in pregnant women

1989 ◽  
Vol 30 (1) ◽  
pp. 82-83
Author(s):  
JH Harger ◽  
AJ Amortegui ◽  
MP Meyer ◽  
GJ Pazin
Keyword(s):  
Herpes Simplex ◽  
Pregnant Women ◽  
Genital Herpes ◽  
Recurrent Genital Herpes

Vaccination with Recombinant Herpes Simplex Virus Glycoproteins: Protection Against Initial and Recurrent Genital Herpes

1987 ◽  
Vol 155 (5) ◽  
pp. 914-920 ◽  
Author(s):  
L. R. Stanberry ◽  
D. I. Bernstein ◽  
R. L. Burke ◽  
C. Pachl ◽  
M. G. Myers
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Genital Herpes ◽  
Recurrent Genital Herpes ◽  
Simplex Virus

scholarly journals Susceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, a Novel Helicase-Primase Inhibitor

2012 ◽  
Vol 56 (7) ◽  
pp. 3587-3591 ◽  
Author(s):  
Kiyomitsu Katsumata ◽  
Adriana Weinberg ◽  
Koji Chono ◽  
Shoji Takakura ◽  
Toru Kontani ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Genital Herpes ◽  
Antiviral Agents ◽  
Term Treatment ◽  
Recurrent Genital Herpes ◽  
Short Term Treatment ◽  
Varicella Zoster ◽  
Simplex Virus ◽  
Hsv 1

ABSTRACTASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. To evaluate the anti-HSV activity of ASP2151, susceptibility testing was performed on viruses isolated from patients participating in a placebo- and valacyclovir-controlled proof-of-concept phase II study for recurrent genital herpes. A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected. ASP2151 inhibited HSV-1 and HSV-2 replication with mean 50% effective concentrations (EC50s) of 0.043 and 0.069 μM, whereas ACV exhibited mean EC50s of 2.1 and 3.2 μM, respectively. Notably, the susceptibilities of HSV isolates to ASP2151 and ACV were not altered after dosing with the antiviral agents. Taken together, these results demonstrate that ASP2151 inhibits the replication of HSV clinical isolates more potently than ACV, and HSV resistant to this novel helicase-primase inhibitor as well as ACV may not easily emerge in short-term treatment for recurrent genital herpes patients.

Sign in / Sign up

Export Citation Format

Share Document